be used. 2022 southern hemisphere The composition of vaccines for use in the 2022 Southern Hemisphere influenza season influenza season recommended by the World Health Organization in September 2021: Egg-based vaccines: A/Victoria/2570/2019 (H1N1)pdm09-like virus; A/Darwin/9/2021 (H3N2)-like virus; B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. Cell- or recombinant-based vaccines: A/Wisconsin/588/2019 (H1N1)pdm09-like virus; A/Darwin/6/2021 (H3N2)-like virus; B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. It is recommended that trivalent influenza vaccines for use in the 2022 southern hemisphere influenza season contain the following: Egg-based vaccines: A/Victoria/2570/2019 (H1N1)pdm09-like virus; A/Darwin/9/2021 (H3N2)-like virus; and B/Austria/1359417/2021 (B/Victoria lineage)-like virus. Cell- or Recombinant-based vaccines: A/Wisconsin/588/2019 (H1N1)pdm09-like virus; A/Darwin/6/2021 (H3N2)-like virus; and B/Austria/1359417/2021 (B/Victoria lineage)-like virus 2022–2023 northern hemisphere The composition of virus vaccines for use in the 2022–2023 Northern Hemisphere influenza season is European Union The composition of virus vaccines for use in the European Union for the 2022–2023 Northern Hemisphere influenza season recommended by the European Medicines Agency on March 29, 2022, is: Quadrivalent egg-based or live attenuated vaccines should contain: an A/Victoria/2570/2019 (H1N1)pdm09-like virus; an A/Darwin/9/2021 (H3N2)-like virus; a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. Quadrivalent cell-culture or recombinant-based vaccines should contain: an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; an A/Darwin/6/2021 (H3N2)-like virus; a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. United States The FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the quadrivalent formulation of egg-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following: an A/Victoria/2570/2019 (H1N1)pdm09-like virus; an A/Darwin/9/2021 (H3N2)-like virus; a B/Austria/1359417/2021-like virus (B/Victoria lineage); and a B/Phuket/3073/2013-like virus (B/Yamagata lineage). The committee recommended that the quadrivalent formulation of cell- or recombinant-based influenza vaccines for the US 2022–2023 influenza season contain the following: an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; an A/Darwin/6/2021 (H3N2)-like virus; a B/Austria/1359417/2021-like virus (B/Victoria lineage); and a B/Phuket/3073/2013-like virus (B/Yamagata lineage). For trivalent influenza vaccines for use in the US for the 2022–2023 influenza season, depending on the manufacturing method of the vaccine, the committee recommended that the A(H1N1)pdm09, A(H3N2) and B/Austria/1359417/2021-like virus (B/Victoria lineage) viruses recommended above for the quadrivalent vaccines be used. Notes References Further reading External links Inactivated Influenza Vaccine Information Statement, US Centers for Disease Control and Prevention (CDC) Live, Intranasal Influenza Vaccine Information Statement, US Centers for Disease Control and Prevention (CDC) Seasonal Influenza (Flu) Vaccination and Preventable Disease, US Centers for Disease Control and Prevention (CDC) Misconceptions about Seasonal Flu and